Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories

被引：38

作者：

Lee S.H. ^{[1
]}

Vigliotti V.S. ^{[1
]}

Vigliotti J.S. ^{[1
]}

Pappu S. ^{[1
]}

机构：

[1] Department of Pathology, Milford Hospital, Milford, CT

来源：

Infectious Agents and Cancer | / 2卷 / 1期

关键词：

Clinical Laboratory Practice;

D O I：

10.1186/1750-9378-2-11

中图分类号：

学科分类号：

摘要：

Background: Human papillomavirus (HPV) genotyping is important for following up patients with persistent HPV infection and for evaluation of prevention strategy for the individual patients to be immunized with type-specific HPV vaccines. The aim of this study was to optimize a robust "low-temperature" (LoTemp™) PCR system to streamline the research protocols for HPV DNA nested PCR-amplification followed by genotyping with direct DNA sequencing. The protocol optimization facilitates transferring this molecular technology into clinical laboratory practice. In particular, lowering the temperature by 10°C at each step of thermocycling during in vitro DNA amplification yields more homogeneous PCR products. With this protocol, template purification before enzymatic cycle primer extensions is no longer necessary. Results: The HPV genomic DNA extracted from liquid-based alcohol-preserved cervicovaginal cells was first amplified by the consensus MY09/MY11 primer pair followed by nested PCR with GP5+/GP6+ primers. The 150 bp nested PCR products were subjected to direct DNA sequencing. The hypervariable 34-50 bp DNA sequence downstream of the GP5+ primer site was compared to the known HPV DNA sequences stored in the GenBank using on-line BLAST for genotyping. The LoTemp™ ready-to-use PCR polymerase reagents proved to be stable at room temperature for at least 6 weeks. Nested PCR detected 107 isolates of HPV in 513 cervicovaginal clinical samples, all validated by DNA sequencing. HPV-16 was the most prevalent genotype constituting 29 of 107 positive cases (27.2%), followed by HPV-56 (8.5%). For comparison, Digene HC2 test detected 62.6% of the 107 HPV isolates and returned 11 (37.9%) of the 29 HPV-16 positive cases as "positive for high-risk HPV". Conclusion: The LoTemp™ ready-to-use PCR polymerase system which allows thermocycling at 85°C for denaturing, 40°C for annealing and 65°C for primer extension can be adapted for target HPV DNA amplification by nested PCR and for preparation of clinical materials for genotyping by direct DNA sequencing. HPV genotyping is performed by on-line BLAST algorithm of a hypervariable L1 region. The DNA sequence is included in each report to the physician for comparison in following up patients with persistent HPV infection, a recognized tumor promoter in cancer induction.

引用

共 52 条

[1] Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E., Walboomers J.M., Meijer C.J., Human papillomavirus- the most significant risk determinant of cervical intraepithelial neoplasia, Int J Cancer, 65, pp. 601-606, (1996)
[2] Human Papillomavirus, Obstet Gynecol, 105, pp. 905-918, (2005)
[3] Wu H.H., Allen S.L., Kirkpatrick J.L., Elsheikh T.M., Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion, Diagn Cytopathol, 34, pp. 707-710, (2006)
[4] Wallin K.L., Wiklund F., Angstrom T., Bergman F., Stendahl U., Wadell G., Hallmans G., Dillner J., Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer, N Engl J Med, 341, pp. 1633-1638, (1999)
[5] Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., Suntum M., Bock J.E., Poll P.A., Meijers C.J., Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study, BMJ, 325, pp. 572-576, (2002)
[6] Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C., McGoogan E., Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study, J Clin Pathol, 58, pp. 946-950, (2005)
[7] Brummer O., Hollwitz B., Bohmer G., Kuhnle H., Petry K.U., Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia, Gynecol Oncol, 102, pp. 517-522, (2006)
[8] Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N., Meijer C.J., Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types, Int J Cancer, 87, pp. 221-227, (2000)
[9] Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J., Balmaceda I., Greenberg M.D., Alfaro M., Burk R.D., Wacholder S., Plummer M., Schiffman M., Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica, J Natl Cancer Inst, 92, pp. 464-474, (2000)
[10] Molano M., Posso H., Weiderpass E., van den Brule A.J., Ronderos M., Franceschi S., Meijer C.J., Arslan A., Munoz N., HPV Study Group HPV Study: Prevalence and determinants of HPV infection among Colombian women with normal cytology, Br J Cancer, 87, pp. 324-333, (2002)

← 1 2 3 4 5 6 →